

# Florence Statement

*Forging the way ahead for more research on and better care in breast cancer*

## Introduction

The first European consensus on key issues in breast cancer has on Saturday 3 October 1998 been reached by nearly 1,000 clinicians, scientists and healthcare consumers attending a mass voting session at the 1<sup>st</sup> European Breast Cancer Conference (EBCC-1) in Florence. The Florence Statement sets the agenda for everyone involved in these key issues in breast cancer research, treatment, prevention and advocacy including the three major groups and organisers of EBCC-1:

- The Breast Cancer Co-operative Group of the European Organization for the Research and Treatment of Cancer (EORTC-BCCG)
- The European Society of Mastology (EUSOMA)
- Europa Donna, the European Breast Cancer Coalition

This objective-setting document will stimulate much needed change in the field of breast cancer. EORTC-BCCG, EUSOMA and the patient-advocacy activities of Europa Donna will work towards these goals by lobbying European governments and mobilizing health-service providers, the scientific community and the healthcare industry. These new actions demanded by the EBCC-1 delegates will be assessed and reviewed in two years at EBCC-2, to be held in Brussels from 26 to 30 September, 2000.



Chairman

Professor L. Cataliotti  
University of Florence, Italy

Conference Secretariat

FECS Conference Unit, Avenue E. Mounier 83, B-1200 Brussels, Belgium  
Tel. +32 - 2 - 775 02 06 / Fax +32 - 2 - 775 02 00

## Florence Statement

Breast cancer is the commonest cancer and the most frequent cause of cancer death in women in every European Union country. Because of its importance and its potentially high curability, breast cancer deserves special attention and effort. The 1<sup>st</sup> European Breast Cancer Conference calls on the European Parliament to devote a plenary session to breast cancer.

The Florence conference also makes the following statements:

On research:

- Clinical trials are the mainstay for the development of optimal treatment of breast cancer and this conference is committed to encouraging maximum participation in clinical trials. Consumers should be fully involved at all stages in the design and conduct of clinical trials, by clear public information, discussion with ethics committees and increased accessibility to clinical trials.
- This conference is committed to the application of pressure on governments, medical charities and the healthcare industry to invest more in breast cancer research, especially into translational studies. In addition, the major European charities are invited to co-ordinate their efforts to avoid unnecessary duplication of research programmes in different countries and thereby release resources to underpin European studies.

On genetic predisposition:

- Given that knowledge about inherited predisposition to breast cancer is constantly emerging and that management options for mutation carriers are still not proven to be of benefit, the conference resolves that genetic testing should be undertaken in the setting of clinical research only. Such a setting needs personnel and facilities to study further the psychological effects and clinical outcomes in those who present for testing.
- Genetic testing represents a potential threat to the privacy and security of women and could lead to commercial exploitation through gene patenting. The conference therefore demands national legislation and a European directive to protect women from personal, professional, financial or other discrimination.

On psychosocial status:

- This conference believes that the measurement of psychosocial status should be mandatory in the assessment and management of women's health and should not just be part of a clinical trial.

On treatment:

- This conference demands that those responsible for organising and funding breast cancer care ensure that all women have access to fully equipped multidisciplinary and multiprofessional breast clinics based on populations of around 250,000.

On quality of care:


- Given the importance of the quality of surgery, radiotherapy and chemotherapy in determining outcome, quality-assurance programmes should become mandatory for breast cancer services to qualify for funding from healthcare providers.
- Evidence-based multidisciplinary management guidelines defined at national and European level with the consensus of healthcare professionals, voluntary organizations, other health-service providers and consumers will further improve outcome.



Professor Luigi Cataliotti  
President EUSOMA



Professor Cornelis van de Velde  
Chairman EORTC-BCCG



Mrs Gloria Freilich  
President Europa Donna